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Abstract: I n t r o d u c t i o n: Dehydration is a  common problem in patients with terminal cancer 
patients. It worsens the quality of life and increases the amount of complications. Factors associated with 
dehydration need further exploration. The aim of our study was to determine the predictors of dehydration.
P a t i e n t s  a n d  m e t h o d s: 102 terminal cancer patients admitted to Palliative Care Unit were 
retrospectively analyzed. Detailed physical examination, medical history including history taken from 
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family and care givers was taken upon admission. Laboratory parameters including morphology, sodium, 
potassium, total and ionized calcium, LDH were taken on admission. We used univariate and multivariate 
logistic regression analysis to determine factors associated with dehydration.
R e s u l t s: On admission 39% of patients were diagnosed with dehydration. Multivariate logistic re-
gression analysis after adjustment for possible confounders reviled that lack of family care (p = 0.006; 
OR = 0.147; CI 95% = 0.038–0.577), higher level of PS (p = 0.0426; OR = 1.65; CI 95% = 1.017–2.667), lack 
of prior opioid use (p = 0.0233; OR = 0.386; CI 95% = 0.17–0.897), occurrence of nausea and vomiting at 
admission (p = 0.0077; OR = 3.297; CI 95% = 1.372–7.922), occurrence of dyselectrolytemia (p = 0.0012; 
OR = 4.462; CI 95% = 1.81–10.997), lack of prior GKS use (p = 0.0362; OR = 0.339; CI 95% = 0.123–0.933); 
lack of prior NSAID use (p = 0.0255; OR = 0.265; CI 95% = 0.082–0.849) remained independently associ-
ated with dehydration. 
C o n c l u s i o n s: Lack of family care, lack of prior opioid use, higher level of PS, occurrence of nausea 
and vomiting at admission, occurrence of dyselectrolytemia, lack of prior GKS use and lack of prior 
NSAID use in patients with terminal cancer are factors associated with dehydration.
Key words: dehydration; cancer patients.
Introduction
Dehydration is a  frequent problem among patients suffering from neoplasia. It 
increases the risk of complications and can worsen a patient’s prognosis and quality of 
life [1–4]. In the majority of patients with late-stage neoplastic disease, we can observe 
a decrease in oral fluid intake, which may result from weakness, anorexia, dysphagia, 
infection of the oral cavity, nausea, vomiting, bowel obstruction, or as a  result of 
medical treatment [5, 6]. Particularly in cases of acute dehydration, it is worthwhile 
to consider parenteral hydration [7]. In such situations, artificial hydration can 
additionally increase a patient’s comfort, as well as decrease pain and fatigue [8]. We 
must remember, however, to ensure that the potential benefits of hydration outweigh 
the risks of acute fluid retention [9]. Therefore, our decision to administer parenteral 
hydration should be made on an individual basis [10–12]. The risk factors associated 
with dehydration require studies involving larger groups of patients [13, 14]. The aim 
of this study was to determine the prognostic factors, symptoms and consequences of 
dehydration in patients suffering from neoplastic disease.
Patients and methods
We retrospectively analyzed the records of 102 patients admitted to the University 
Hospital Palliative Medicine Department in Krakow, Poland. On admission, 
a  thorough patient history (from patients and/or their families or caregivers) and 
physical examination were performed. Additionally, laboratory tests were ordered 
including: complete blood count, electrolytes (sodium, potassium, total and ionized 
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calcium), and serum lactate dehydrogenase activity (LDH). Of the 102 patients 
analyzed, 57 were male and 45 were female. The presence of dehydration was 
assessed on the basis of a  structured patient history and the results of the physical 
examination. As part of the history, special attention was paid to the patient’s level 
of thirst and amount of urine. During physical examination, dryness of oral and 
lingual mucosa was assessed, as well as skin turgor. Our study received ethic approval 
from the Jagiellonian University Bioethical Committee (nr 122.6120.169.2016) on 
June 23, 2016.
Statistical methods
Univariate and multivariate logistic regression analysis was performed to determine 
the prognostic factors, symptoms and effects of dehydration. After checking 
normality of the data, we subsequently analyzed the data using the student’s t-test 
(for independent samples) or the Mann-Whitney test in order to better visualize the 
results. Results with p <0.05 were considered statistically significant. All statistical 
analysis was performed using Statistica v. 12 for Windows (Statsoft Polska).
Results
Among the analyzed patients, 39% had clinical features of dehydration on admission. 
The average patient age was 66.64 years and the average length of stay on the ward 
was 15 days. One-third of patients from the study group were admitted to the 
Palliative Medicine Department from the Emergency Department as an emergent 
admission. Nearly half of the analyzed (50 patients) were eventually discharged home. 
Hospitalization resulted in death for the remaining patients. The most common type 
of neoplasia in the study group was lung cancer (26.47%). The next most frequent 
types of neoplasia were pancreatic (10.78%), breast (9.8%), colorectal (8.82%), and 
prostate (7.84%). Distant metastasis was confirmed in 92 of the patients, including 
19  patients with metastasis to the central nervous system and 37 with metastasis 
to bone.
Upon  univariate  logistic  regression  analysis,  the  statistically  significant 
prognostic factors were found to be (Table 1): family care (p = 0.002; OR = 0.147; 
CI 95% =  0.038–0.577), lack of NSAID use prior to hospitalization (p = 0.019; 
OR = 0.265; CI 95% = 0.082–0.849), lack of GCS use prior to hospitalization 
(p = 0.032; OR = 0.339; CI 95% = 0.123–0.933), and lack of opioid use prior to 
hospitalization (p = 0.022; OR = 0.386; CI 95% = 0.17–0.879). Patients in a  worse 
physical state (higher score in PS scale) had a  greater chance of being dehydrated 
(p = 0.039; OR = 1.65; CI 95% = 1.017–2.667). After checking normality, the data 
was analyzed using the student’s t-test (for independent samples) or the U Mann-
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Whitney test. We found that properly hydrated patients were being cared for by 
family members in 95.16% of cases, whereas dehydrated patients were receiving 
such care in only 74.35% of cases. Analysis of patients who had received treatment 
before admission revealed that 30.16% of properly hydrated patients took NSAIDs 
for analgesia, while only 10.26% of dehydrated patients had taken them. The second 
group of drugs which was analyzed were GCS. 34.92% of properly hydrated patients 
were receiving GCS before admission, while only 15.38% of dehydrated patients were 
receiving them. The final group of drugs which we analyzed were opioids. 66.67% 
of well hydrated patients were taking opioids before hospitalization, whereas only 
43.59% of dehydrated patients were taking medications from this group.
Table 1. Factors predisposing patients to dehydration.
Risk factor Properly hydrated patients (n = 63)
Dehydrated patients 
(n = 39) p-value
Active cancer treatment 0.238095 0.230769 0.933278
Family care 0.951613 0.743590 0.021130
NSAID use prior to admission 0.301587 0.102564 0.019261
Antidepressant use prior to admission 0.174603 0.256410 0.325544
Anticonvulsant use prior to admission 0.142857 0.179487 0.625163
GCS use prior to admission 0.349206 0.153846 0.031817
Opioid use prior to admission 0.666667 0.435897 0.021709
Hospice or palliative care 0.349206 0.230769 0.210147
PS score 2.825397 3.205128 0.039059
Based on these results, we can infer that the use of NSAIDS and opioids resulted 
in better pain control among patients. This lead to an increase in homeostasis and 
consequently better hydration. It should be noted, however, that the combined use of 
GCS and NSAIDs, particularly in dehydrated patients, can increase the risk of adverse 
effects. GCS are among the most commonly used medications to relieve symptoms in 
the advanced stage of neoplastic disease. Rapidly progressive dehydration, hypotension, 
and oliguria may be signs of acute secondary adrenal insufficiency, which may be 
caused by a sudden withdrawal of long-term GCS treatment. Overlapping symptoms 
of adrenal insufficiency and neoplastic disease or misinterpretation of laboratory 
results as renal failure, especially in patients with exacerbated adrenal insufficiency, 
may lead to misdiagnosis.
Another parameter we evaluated was the degree of physical disability in patients 
with neoplastic disease. To evaluate this, we used the PS scale. According to this scale, 
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an increase in PS score indicates a  worsening of a  cancer patient’s general status, 
which may lead to disturbances in homeostasis and a greater risk of dehydration. The 
average PS score in our study group was 2.83 for properly hydrated patients. However, 
it was significantly higher for dehydrated patients, averaging 3.21.
Further univariate logistic regression analysis of the occurrence of certain 
symptoms in patients was performed (Table 2). We found that nausea and vomiting 
at admission was a  statistically significant symptom of dehydration (p = 0.0061; 
OR = 3.297; CI 95% = 1.372–7.922) (Fig. 1). While 20.63% of well hydrated patients 
reported nausea and vomiting at admission, the rate for dehydrated patients was more 
than two times higher, measuring 46.15%.
Table 2. Symptoms of dehydration.
Symptom at admission Properly hydrated patients (n = 63)
Dehydrated patients 
(n = 39) p-value
Anxiety 0.380952 0.333333 0.630952
Constipation 0.349206 0.384615 0.721003
Nausea/vomitting 0.206349 0.461538 0.006136
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Fig. 1. Correlation between nausea/vomiting at admission and dehydration among patients. 
 
 
 
Fig. 2. Correlation between the occurrence of dyselectrolytemia and dehydration among patients. 
 
 
 
Fig. 1. Correlation between nausea/vomiting at admission and dehydration among patients.
The next univariate logistic regression analysis was performed in regards to the 
effects of dehydration (Table 3). It was revealed that dyselectrolytemia is a statistically 
significant effect of dehydration (p = 0.000646; OR = 4.462; CI 95% = 1.81–10.997) 
(Fig. 2). Dyselectrolytemia was diagnosed in 41.94% of patients who were properly 
hydrated, but was markedly more frequent among dehydrated patients, being 
diagnosed in 76.32%.
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Table 3. Effects of dehydration.
Effect Properly hydrated patients (n = 63)
Dehydrated patients 
(n = 39) p-value
Weightloss >30% 0.322581 0.512821 0.057860
Dyselectrolytemia 0.419355 0.763158 0.000646
Neuropsychiatric symptoms during 
hospitalization 0.428571 0.481790 0.567713
Neuropsychiatric symptoms at discharge 0.333333 0.333333 1.000000
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Fig. 1. Correlation between nausea/vomiting at admission and dehydration among patients. 
 
 
 
Fig. 2. Correlation between the occurrence of dyselectrolytemia and dehydration among patients. 
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The final phase of our analysis consisted of multivariate logistic regression analysis 
(Table 4). In this phase, we analyzed factors interacting with each other in complex 
model and having an influence on dehydration, as well as those independent from 
other factors. Our results showed that the independent prognostic factors associated 
with dehydration are: family care (p = 0.006; OR = 0.147; CI 95% = 0.038–0.577), 
NSAID use before hospitalization (p = 0.0255; OR = 0.265; CI 95% = 0.082–0.849); 
GCS use before hospitalization (p = 0.0362; OR = 0.339; CI 95% = 0.123–0.933), 
opioid use before hospitalization (p = 0.0233; OR = 0.386; CI 95% = 0.17–0.897), and 
PS score (p = 0.0426; OR = 1.65; CI 95% = 1.017–2.667). Family care reduces the 
chance of dehydration by 6.8 times. Medication use before hospitalization also reduces 
the risk of dehydration (NSAIDS by 3.8x, GCS by 3x, opioids by about 2.6×). An 
increase of 1 unit on the PS scale results in a 1.7 times greater chance for the presence 
of dehydration. Nausea and vomiting at admission is the only symptom independently 
associated with dehydration (p = 0.0077; OR = 3.297; CI 95% = 1.372–7.922), 
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occurring 3.3 times more frequently among dehydrated patients. Dyselectrolytemia 
is an independently associated effect of dehydration (p = 0.0012; OR = 4.462; CI 
95% = 1.81–10.997) and occurs 4.5 times more frequently in patients suffering from 
dehydration.
Table 4. Multivariate regression analysis of factors associated with dehydration.
Factor p-value OR 95% CI Rate  
Family care 0.0060 0.147 0.038–0.577 6.8x ↓
Pr
og
no
st
ic
 fa
ct
or
s
NSAID use prior to admission 0.0255 0.265 0.082–0.849 3.8x ↓
GCS use prior to admission 0.0362 0.339 0.123–0.933 3.0x ↓
Opioid use prior to admission 0.0233 0.386 0.170–0.897 2.6x ↓
PS score 0.0426 1.650 1.017–2.677 1.7x ↑
Nausea/ vomitting at admission 0.0077 3.297 1.372–7.922 3.3x ↑ Symptom
Dyselectrolytemia 0.0012 4.462 1.810–10.997 4.5x ↑ Consequence
The above analyses indicate that the factors contributing to dehydration in 
advanced cancer patients admitted to a hospital ward as an emergency admission are: 
lack of family care at home, lack of medication usage (GCS, NSAIDs, opioids), higher 
score on the PS scale, occurrence of nausea and vomiting, and laboratory-confirmed 
dyselectrolytemia.
Discussion
Patients in the terminal phase of neoplastic disease are at high risk of dehydration [1]. 
Effective symptom control and optimization of therapy and clinical status in this 
phase of disease can result in many benefits, including proper maintenance of 
a  patient’s fluid-electrolyte balance [8, 14]. Our results appear to be clinically useful, 
as they allow us to identify factors which can potentially lower the risk of dehydration 
in patients suffering from advanced neoplasia. The results indicate a  need for the 
optimization of pain control in patients receiving outpatient palliative care. In the 
treatment of this pain, we should use drugs ranging from non-opioid analgesics to 
strong opioids, depending on pain severity, in accordance with the recommendations 
of the World Health Organization and European Association of Palliative Care.
GCS are medications administered via several routes, including parenteral, for 
a variety of specific and non-specific indications. In palliative medicine, they are most 
frequently used for non-specific indications. Therefore, one must plan to administer 
them for approximately 3–4 weeks. These drugs limit inflammation, thus promoting 
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homeostasis and reducing the risk of dehydration. However, it is important to 
remember that in many patients, after an initial improvement, the therapeutic effect 
of GCS decreases despite continued administration, and the risk of adverse effects 
quickly increases, due to long-term disruption of the hypothalamic-pituitary axis. As 
the results of our study show, the problem of dehydration in patients admitted to the 
hospital is also related to care from family members in the outpatient setting. It is 
therefore worthwhile to discuss with family members the important role their care 
plays in limiting the risk of dehydration. Nausea and vomiting are also important risk 
factors of dehydration in patients with cancer, who are not receiving chemotherapy. 
However, in patients receiving this therapy, they are the most frequent side effects 
and we should, therefore, bring this to the attention of the family. Thus, proper 
oral hydration in the outpatient setting can potentially decrease the risk of rapid 
deterioration of a patient’s general status.
Our observations demonstrating a  clear correlation between number of nausea/
vomiting states and dehydration in our study group was confirmed in six other 
studies [5, 14]. In patients who display clinical signs of dehydration (dryness of 
mucous membranes, oliguria, decreased skin turgor, etc.), electrolyte levels should 
be measured. According to our results, dyselectrolytemia occurs almost 5 times 
more frequently in dehydrated individuals. Several other investigators also noted 
the need to monitor electrolytes in dehydrated patients [6, 15]. It should be noted 
that electrolyte disturbances must be corrected slowly. In clinical practice, correcting 
sodium levels too quickly can result in severe neurologic consequences (central 
pontine myelinolysis), and a sudden rise in potassium can lead to cardiac arrest [15].
Insufficient fluid intake associated with weakness, coexisting renal insufficiency, 
potential for diarrhea, and increased hyperventilation in febrile patients promotes 
the development of dehydration and a  decreased amount of water in the intra- 
and extracellular space. These conditions may lead to hyperosmolarity with the 
following clinical manifestations: nausea, lassitude, muscle weakness, disturbances of 
consciousness [15, 16]. Plasma hyperosmolarity leads to stimulation of osmoreceptors 
in the hypothalamus and secretion of anti-diuretic hormone (ADH) [17]. ADH 
increases the reabsorption of water leading to a reduction in plasma osmolarity and, 
consequently, to hyponatremia, which significantly increases the risk of death [1]. The 
fluid deficit observed in our patients also promotes the development of symptoms of 
confusion. In previously published studies, the authors of three independent papers 
recognized that dehydration and the administration of large doses of opioids were 
the two main causes of qualitative disturbances of consciousness [6, 12, 18, 19]. It is 
believed that hydration is a potential method for reversing this undesirable condition 
in these patients [1, 20].
Finally, it is worth noting that hydration is a  controversial topic in palliative 
medicine and is associated with quite divergent opinions. Research on this topic 
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is mixed. We must take clinical and socio-cultural conditions into account when 
determining our approach. Preferences of the patient and family should be respected. 
In emergency cases of dehydration (vomiting, diarrhea), physicians should weigh the 
benefits of parenteral hydration. When deciding on the route of hydration, one should 
consider the fact that intravenous fluid administration may be inconvenient and 
unpleasant for patients. It is worth remembering that subcutaneous infusion remains 
a good alternative method of hydration in terminal cancer patients. Hydration can be 
beneficial, but the decision to begin this treatment should be made on an individual 
basis. It is also recommended that properly hydrated patients in the terminal phase 
should receive reduced doses of medications, to reduce the risk of adverse effects [7].
In conclusion, analysis of our data indicates that the factors contributing to 
dehydration in patients with advanced neoplastic disease, admitted to a hospital ward 
as an emergency admission, are: lack of family care at home, lack of medication usage 
before hospitalization (GCS, NSAIDs, opioids), higher PS score, presence of nausea 
and vomiting, and laboratory-confirmed dyselectrolytemia.
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(attempts to determine the general status and quality of life in patients 
with neoplastic disease)
OR — odds ratio
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